In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on VistaGen Therapeutics, with a price target of $12.00.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Jason McCarthy’s rating is based on several compelling factors. VistaGen Therapeutics has recently completed its Phase 3 PALISADE-3 study for fasedienol, a treatment for social anxiety disorder, with results expected by the end of 2025. This study, along with the ongoing PALISADE-4 study, represents significant potential catalysts for the company, especially given the prior success of the PALISADE-2 study.
Fasedienol stands out as a promising candidate in the market, particularly after a competitor’s recent failure to meet primary endpoints in a similar study. This positions fasedienol as a potential first-in-class treatment for social anxiety disorder, a significant unmet need. The stock has already seen a substantial increase in value, reflecting investor optimism. Additionally, the company’s strategic plans for commercialization and revenue projections further support the Buy rating, with a 12-month price target set at $12.
In another report released on November 1, William Blair also reiterated a Buy rating on the stock with a $0.00 price target.